<DOC>
	<DOCNO>NCT00001383</DOCNO>
	<brief_summary>This dosage escalation study estimate maximum tolerate dose drug resistance inhibitor PSC 833 give combination paclitaxel . Groups 3 6 patient receive continuous-infusion paclitaxel 5 day oral PSC 833 6-7 day , follow paclitaxel first course , begin 3 day prior paclitaxel subsequent course . Stable respond patient re-treated every 21 day , paclitaxel dose adjust maintain absolute neutrophil count less 500 4 day .</brief_summary>
	<brief_title>A Phase I Study Infusional Paclitaxel With P-Glycoprotein Antagonist PSC 833</brief_title>
	<detailed_description>The clinical study entitle `` A Phase I Study Infusional Paclitaxel P-glycoprotein Antagonist PSC 833 '' seek determine maximum tolerate dose propose P-glycoprotein antagonist , PSC 833 , combination paclitaxel . PSC 833 cyclosporine analogue purportedly non-nephrotoxic non-immunosuppressive . It show vitro study enhance chemosensitivity well cyclosporine far well increase intracellular drug accumulation concentration verapamil clinically achievable . The purpose study define maximum tolerate dose combination paclitaxel , determine drug affect pharmacokinetics paclitaxel . PSC 833 likely reduce clearance paclitaxel report parent compound , cyclosporine . This effect increase area curve ( AUC ) paclitaxel , may increase toxicity , require escalation scheme PSC 833 conservative one . The first cycle paclitaxel give absence PSC 833 . Subsequently , 7 day PSC 833 give alone allow monitoring pharmacokinetics adverse effect PSC 833 alone . In second cycle , agent combine . Escalation PSC 833 continue target concentration reach , maximum tolerate dose reach . Clinical response monitor order provide best possible medical care patient .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Biopsy proven advance cancer , good therapy exists . Enrollment patient breast cancer , lymphoma , renal cell cancer ovarian cancer encourage . Patients life expectancy least 16 week , performance status ( Karnofsky Scale ) 70 % great . No rapidly grow disease . Patients prior therapy . WBC great 3,000/mm ( 3 ) AGC great 1000/mm ( 3 ) ; platelet great 100,000/mm ( 3 ) . Creatinine clearance great 50 ml/min ; bilirubin less 1.5 mg/dl ; SGOT le 90 u/L ; SGPT le 100 u/L . Patients must sign informed consent geographic accessibility return follow treatment . No history brain metastasis . No patient currently receive treatment follow agent agent know significantly interact cyclosporine , treatment discontinue , change another therapeutically equivalent allowable drug : acetazolamide , barbiturate , corticosteroid , diltiazem , erythromycin , fluconazole , ketoconazole , nicardipine , phenothiazine , phenytoin , rifampin , sulfonamide , trimethoprim , verapamil , tamoxifen , progesterone , quinine , quinidine , amiodarone . No patient history coronary artery disease angina pectoris history congestive heart failure . No patient history cardiac disease , angina pectoris congestive heart failure , include patient arrhythmias conduction system abnormality consider individual basis . No patient symptomatic peripheral neuropathy ( grade 2 great ) . No patient positive serology HIV . No patient pregnant unwilling practice adequate contraception . No patient prior bone marrow transplantation extensive irradiation result compromise bone marrow reserve .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>Cyclosporine Analogue</keyword>
	<keyword>Multidrug Resistance</keyword>
	<keyword>Pgp Blocker</keyword>
	<keyword>Pump Blocker</keyword>
	<keyword>Taxol Over 90 Hours</keyword>
</DOC>